在脏移植中使用矿物甲类皮质体受体对手
Mehmet Kanbay1, Sidar Copur2, Berk Mizrak2
1Division of Nephrology, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey.
European journal of clinical investigation
|April 5, 2024
概括
矿物甲基皮质类受体抗剂对移植接受者来说是有前途的,可能会改善蛋白尿和毒性等结果. 需要进一步的大规模试验来确认它们的长期安全性和有效性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
背景情况:
- 氨酸- ангиотензин- алдостерон系统在慢性病,心力衰竭,高血压和蛋白尿症中至关重要.
- 矿物质皮质类受体对抗剂是阻断该系统的关键,与ACE抑制剂和ARB一起.
研究的目的:
- 审查矿物质皮质类受体对抗剂在移植接受者的疗效和安全性.
- 探索与它们在这个人群中的使用相关的潜在病理生理学.
主要方法:
- 现有临床前和临床研究的叙述性综述.
- 对安全性和疗效数据的评估.
主要成果:
- 矿类皮质类受体对抗剂对非移植患者的慢性病和蛋白尿有效.
- 在移植接受者的有限但有前途的数据表明,对缺血-再输损伤,蛋白尿和氨酸抑制剂诱导的毒性有好处.
- 低血压和高血等不良事件并没有显著增加.
结论:
- 在移植受体中,对矿物质皮质类受体抗剂的初步发现令人鼓舞.
- 大规模的长期随机临床试验对于验证这些有希望的结果至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Antihypertensive Drugs: Potassium-Sparing Diuretics
534
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
534
Antihypertensive Drugs: Direct Renin Inhibitors
616
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
616
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
627
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627


